Please login to the form below

Not currently logged in
Email:
Password:

idelalisib

This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

R&D productivity takes off

R&D productivity takes off

nitro-dihydro-imidazooxazole drug for multidrug-resistant tuberculosis (MDR-TB); Gilead Sciences' Zydelig (idelalisib) for certain types of leukaemia and lymphoma, which inhibits a protein that plays a role in the

Latest news

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Capturing "in-the-moment" patient and physician insights
Utilising the benefits of mobile technology...
Webinar: Observational Research
Presenting a window on the world of your customer...
Webinar: The Brazil Conundrum
Conducting research in one of the world's largest pharma markets...